Jerry Centeno, MD
Cardiovascular Disease · Flushing, NYNPI 1508220856
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,373 of the $2,685 with a category attached, or 88.4%. 19 manufacturers reported payments, led by Boehringer Ingelheim at 28.8% of the total. Reporting peaked in 2023 at $802 and has fallen 85.0% since, to $120 in 2024.
Across 44 payments — averaging $61.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$774
- Abiomed$242
- GSK$220
- Boston Scientific$213
- Theratechnologies Inc.$213
- Amgen$180
- plus $842 from 13 others
What the payments were for
- Food & beverage$2,37388%
- Education$31212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $774 |
| Abiomed | 3 | $242 |
| GSK | 2 | $220 |
| Boston Scientific | 2 | $213 |
| Theratechnologies Inc. | 3 | $213 |
| Amgen | 3 | $180 |
| Johnson & Johnson | 4 | $135 |
| Mallinckrodt Enterprises LLC | 1 | $125 |
| Abbott | 3 | $110 |
| Astellas Pharma US Inc | 1 | $99 |
| Mallinckrodt Hospital Products Inc. | 1 | $95 |
| AstraZeneca | 1 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Merck | 2 | $44 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Viiv Healthcare Company | 1 | $24 |
| Shionogi Inc | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$220
- Impella$168
- GENERAL BRADY$138
- ACTHAR$125
- Repatha$124
- EGRIFTA SV$120
- OFEV$112
How this compares
$2,685 in reported general payments places this provider in the 60th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 13 | $160 |
| Carvedilol | 17 | $96 |
| Metoprolol Succinate | 18 | $70 |
| Losartan Potassium | 11 | $67 |
| Amlodipine Besylate | 16 | $16 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Flushing
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.